On this site you will find clinical studies with cannabis or single
cannabinoids in different diseases and case reports on the use of cannabis by
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.
|Title||Treating non-cognitive symptoms of people with dementia|
|Journal, Volume, Issue|
|Major outcome(s)||Nabilone improves agitation and other behavioural symptoms in patients with Alzheimer’s disease|
Results of a double-blind clinical trial presented at the Alzheimer's Association International Conference (AAIC) 2018 in Chicago suggest that nabilone may be effective in treating agitation in people with Alzheimer's disease. Nabilone is a synthetic THC derivative. The study with adults with moderate to severe Alzheimer's dementia was led by Dr Krista L. Lanctôt, Professor of Psychiatry and Pharmacology/Toxicology at the University of Toronto, Canada.
Over the 14-week trial duration, 39 participants (77 percent male, average age 87) received nabilone in capsule form (mean dose: 1.6 mg) for six weeks, followed by six weeks of placebo, with one week between each treatment period. In addition to measuring agitation, the researchers assessed overall behavioural symptoms, memory and physical changes. They found that agitation and overall behaviour improved significantly. The researchers also observed small benefits in cognition and nutrition during the study.
|Type of publication||Meeting abstract;Online publication|
|Address of author(s)|